Dow Chemical to acquire Rohm and Haas
This article was originally published in Scrip
Executive Summary
Dow Chemicalhas reached a definitive agreement to acquire the speciality chemical company Rohm and Haasfor more than $15 billion, to create the world's leading speciality chemicals and advanced materials company. It will pay $78 in cash for each outstanding share, a more than 73% premium to Rohm and Haas's closing share price on July 9th. The move into more high-margin speciality chemicals should help protect Dow from the more cyclical basic chemical sales business, and it described it as a decisive move to transform Dow into an earnings growth company. Rohm and Haas is best known for its paint and electronics materials businesses but its technologies are found in a wide range of industries, including pharmaceuticals. The deal, which has been unanimously approved by the boards of both companies, remains subject to approval by Rohm and Haas shareholders and regulatory approvals.
You may also be interested in...
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.